Schott Pharma AG & Co KGaA
Schott Pharma AG & Co KGaA/ DE000A3ENQ51 /
1SXP/D
|
2024-12-20 5:21:34 PM
|
Chg.
+0.27
|
Volume |
Bid5:30:00 PM |
Ask5:30:00 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
24.29EUR
|
+1.12%
|
98,633
Turnover: 1.35 mill. |
-Bid Size: - |
-Ask Size: - |
3.66 bill.EUR |
0.66% |
24.57 |
Business description
For more than 100 years, the SCHOTT name has represented advanced solutions and services for the global pharmaceutical and biotech industries. With this longstanding expertise, SCHOTT Pharma provides an extensive and scientifically proven product portfolio for the safe storage and administration of injectable drugs to patients all over the world.
SCHOTT Pharma`s portfolio ranges from prefillable syringes, cartridges, vials, and ampoules to analytical, development, fill-and-finish, and regulatory services for pharmaceutical companies, biotechs, and CDMOs.
Management board & Supervisory board
| CEO |
| Andreas Reisse |
| Management board |
| Dr. Almuth Steinkuhler |
| Supervisory board |
| Peter Goldschmidt, Dr. Wolfgang Wienand, Ann-Kristin Erkens , Eva Kienle, Christine Wening, Mario Just |
Company data
| Name: |
SCHOTT PHARMA INH O.N. |
| Address: |
Hattenbergstrasse 10,Mainz, 55122 |
| Phone: |
- |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.schott-pharma.com/ |
| Industry: |
Healthcare |
| Sector: |
Medical Products |
| Sub sector: |
Medical Supplies |
| End of financial year: |
09-30 |
| Free Float: |
23.00% |
| IPO date: |
2023-09-28 |
Company calendar
|
CW 6 | 2025-02-04
General Shareholder Meeting
|
|
CW 6 | 2025-02-05
Ex-Dividend
|
|
CW 6 | 2025-02-06
Record Date
|
|
CW 6 | 2025-02-07
Dividend Payment
|
|
CW 7 | 2025-02-13
Interim Report 1st Quarter/3 Months
|
